

Name of the Issue: Akem Laboratories Limited

1	Type of Issue	Initial Public Offer
2	Issue Size (INR m)	13,466.22* 13,477.64**

*Source: Prospectus dated December 15, 2015

**Source: Basis of allotment-pursuant to spill over of undersubscription in Employee category to Net offer

3	Grade of issue along with name of the rating agency	
	Name	N.A.
	Grade	N.A.

4	Subscription Level (Number of times)	30.87 *
	* Before technical rejections and after adjusting for cheque return cases Source: Minutes for basis of allotment dated December 19, 2015	

5	QIB Holding (as a % of Outstanding Capital) as disclosed to the stock exchanges	
	Particulars	%age
	(i) On Allotment *	5.30%
	(ii) at the end of the 1st Quarter immediately after the listing of the issue (December 31, 2015)	6.00%
	(iii) at the end of 1st FY (March 31, 2016)	6.80%
	(iv) at the end of 2nd FY (March 31, 2017)	6.80%
	(v) at the end of 3rd FY (March 31, 2018)	6.92%

* Minutes for basis of allotment dated December 19, 2015 Source: BSE

6	Financials of the issuer			
		(INR Million)		
	Parameters	1st FY (March 31, 2016)	2nd FY (March 31, 2017)	3rd FY (March 31, 2018)
	Income from operations	49,915	58,526	64,312
	Net Profit for the period	6,731	9,047	6,884
	Paid-up equity share capital	239	239	239
	Reserves excluding revaluation reserves	34,787	44,437	48,399

7	Trading Status in the scrip of the issuer	
	The company's equity shares are listed on the BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE") The shares have not been suspended or delisted	
	Particulars	Status
	(i) at the end of 1st FY (March 31, 2016)	Frequently traded
	(ii) at the end of 2nd FY (March 31, 2017)	Frequently traded
	(iii) at the end of 3rd FY (March 31, 2018)	Frequently traded

8	Change in Directors of Issuer from the disclosures in the offer document		
	Particulars	Name of Director	Appointed / Resigned
	(i) at the end of 1st FY (March 31, 2016)	None	None
	(ii) at the end of 2nd FY (March 31, 2017)	None	None
	(iii) at the end of 3rd FY (March 31, 2018)	Mr. Manqaldas Chhaqanlal Shah	Resigned
		Dr. Sheeral Sharma	Appointed
		Mr. Sandeep Singh	Appointed

9	Status of implementation of project/ commencement of commercial production	
	(i) as disclosed in the offer document	
	(ii) Actual implementation	Not Applicable as 100% offer for sale
	(iii) Reasons for delay in implementation, if any	

10	Status of utilization of issue proceeds	
	(i) As disclosed in the offer document	
	(ii) Actual utilization	Not Applicable as 100% offer for sale
	(iii) Reasons for deviation, if any	

11	Comments of monitoring agency	
	Not Applicable as 100% offer for sale	
	(i) Comments on use of funds	
	(ii) Comments on deviations, if any, in the use of proceeds of the Issue from the objects stated in the Offer document	Not Applicable
	(iii) Any other reservations expressed by the monitoring agency about the end use of funds	

12 Pricing Data

Designated Stock Exchange BSE
 Issue Price (Rs.) 1050.0*
 Listing Date 23-Dec-15
 * Discount of Rs. 100 was offered to Eligible Employees of the Issuer

	Close of 30thcalendar day from listing day ¹ Jan 21, 2016		At close of 90thcalendar day from listing day ² Mar 21, 2016		As at the end of the 1st FY after the listing of the issue (March 31, 2016)		
	At close of listing day Dec 23, 2015	High ³	Low ³	Closing price	High ³	Low ³	
Market Price (BSE)	1,352	1,368	1,348	1,367	1,389	1,354	
Index (of the Designated Stock Exchange): BSE	25,850	23,962	25,295	25,342	25,490	25,223	
Sectoral Index (BSE Healthcare)	16,716	15,174	15,442	15,149	15,192	15,090	
		As at the end of the 2nd FY after the listing of the issue (March 31, 2017)		As at the end of the 3rd FY after the listing of the issue (March 31, 2018)			
	Closing price	High ³	Low ³	Closing price	High ³	Low ³	
Market Price (BSE)	2,207	2,229	2,153	1,926	1,983	1,920	
Index (of the Designated Stock Exchange): BSE	29,621	29,688	29,553	33,255	33,289	32,998	
Sectoral Index (BSE Healthcare)	15,312	15,346	15,283	13,484	13,502	13,208	

Source: Stock Exchange data

(1) 30th calendar day has been taken as listing date plus 29 calendar days. Where the 30th day is a holiday the immediately following trading day has been considered
 (2) 90th calendar day has been taken as listing date plus 89 calendar days. Where the 90th day is a holiday the immediately following trading day has been considered
 (3) Intraday high low prices for Mar 31 considered

13 Basis for Issue Price

	As disclosed in the offer document*	At the end of 1st FY (March 31, 2016)	At the end of 2nd FY (March 31, 2017)	At the end of 3rd FY (March 31, 2018)
	Alkem	38.7	56.3	74.6
	Peer Group:			52.7
EPS (Basic)	Torrent Pharmaceutical Limited	44.4	101.8	55.2
	IPCA Laboratories Limited	20.1	7.4	18.5
	Alembic Pharmaceutical Limited	15	38.2	21.9
	Industry Avg	NA	NA	NA
	Alkem	27.1	24.3	29.6
	Peer Group:			36.55
P/E (1)	Torrent Pharmaceutical Limited	34.8	13.2	28.1
	IPCA Laboratories Limited	38.8	78.5	40.4
	Alembic Pharmaceutical Limited	45.2	15.7	29.2
	Industry Avg	NA	NA	NA
	Alkem	15.4	19.5	21.9
	Peer Group:			19.1%
RoNW	Torrent Pharmaceutical Limited	30.2	50.8	23.8
	IPCA Laboratories Limited	11.5	4.2	8.3
	Alembic Pharmaceutical Limited	32	45	23
	Industry Avg	NA	NA	NA
	Alkem	250.5	292.9	383.3
	Peer Group:			406.8
NAV per share	Torrent Pharmaceutical Limited	147.2	200.3	257.1
	IPCA Laboratories Limited	175	181	194.6
	Alembic Pharmaceutical Limited	46.9	84.9	100.9
	Industry Avg	NA	NA	NA

Notes

* Sourced from prospectus dated December 15, 2015

* Not available as the relevant fiscal year financial statements have not been disclosed

(1) At the issue price of INR 1,050 divided by EPS (Basic) for listing date only

14 Any other material information

Particulars	Date
Some of the promoters of Alkem Laboratories Limited ("Company") comprising of Mr. Sampada Singh and his lineal descendants, Mr. Balmiki Prasad Singh, Mrs. Manju Singh, Mr. Sarandhar Singh, Mr. Srinivas Singh, Mr. Satish Kumar Singh, Mrs. Premilata Singh, Mr. Sarvesh Singh, Mrs. Annapurna Singh, Mr. Sandeep Singh and Mrs. Inderjit Arora, and the Sampada Singh HUF have entered into a family settlement on March 23, 2016 with a view to ensure preservation of the shareholding and control of the Company within the family. Pursuant to the family settlement, the aforementioned members of the family will transfer their shareholding to a family trust. The transfer to the trust will be done only after receipt of an exemption under the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 from the Securities and Exchange Board of India. It is to be noted that such an arrangement will not result in any change in management and control of the Company.	23-Mar-16

Note: For further updates and information, please refer stock exchange websites i.e. www.bseindia.com and www.nseindia.com